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Abstract 
Introduction 
The epidermal growth factor receptor (EGFR), a transmembrane receptor 
with tyrosine kinase activity, regulates cellular proliferation. In a subset of 
non-small cell lung cancers (NSCLC), gatekeeper mutations in the EGFR 
kinase domain induce constitutive activation of the receptor causing uncon-
trolled cell growth. Osimertinib, an irreversible third-generation EGFR ty-
rosine kinase inhibitor (EGFR-TKI), prevents cell cycle progression by se-
lectively targeting both EGFR-TKI-sensitizing mutations and EGFRT790 
resistance mutations, while sparing wild-type EGFR function.  
Methodology  
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials. Furthermore, the magnitude of clinically 
meaningful benefit that can be expected from osimertinib was evaluated 
based on, both the Magnitude of Clinical Benefit Scale developed by the Eu-
ropean Society for Medical Oncology. 
Results of the FLAURA trial 
In the phase III, FLAURA study 556 patients with untreated advanced 
EGFR-mutated NSCLC were randomised 1:1 to osimertinib or standard of 
care (SoC) until disease progression or unacceptable toxicity. Compared 
with SoC EGFR-TKIs, osimertinib increased investigator-assessed median 
progression-free survival (PFS) by 8.7 months, and lowered the risk of dis-
ease progression or death by 54%. The PFS benefit was consistent across 
subgroups regardless of Asian or non-Asian race, Ex19del or L858R EGFR 
subtype, and presence or absence of central nervous system (CNS) metasta-
ses. Overall survival (OS) data were immature at interim analysis; however, 
83% of osimertinib patients and 71% of SoC patients achieved 18-month 
survival. Grade ≥3 AEs were less common in the osimertinib group com-
pared to SoC (34% versus 45%); however, decreased appetite (3%), pneumo-
nia (2%), diarrhoea (2%), and prolonged QTc (2%) were most common. 
Cardiac and lung effects occurred more frequently in the osimertinib group 
than in the SoC group (10% and 4% versus 5% and 2%, respectively); nota-
bly cardiac failure (4%), prolonged QTc interval (10%), and interstitial lung 
disease (4%).  
Conclusion 
Overall, FLAURA is the first phase III, randomized, double-blind, compara-
tive trial to demonstrate that osimertinib substantially increases PFS and 
lowers the risk of disease progression compared to first-generation EGFR-
TKI as initial therapy for EGFR-mutated advanced NSCLC. The PFS bene-
fit was consistent across subgroups regardless of race, EGFR subtype, and 
presence of CNS metastases. OS and quality of life data are needed to con-
firm patients achieve a clinically relevant benefit over time despite favoura-
ble tolerability. Currently, the optimal therapeutic sequencing of different 
generations of EGFR-TKI remains unknown. Further analyses are necessary 
to fully characterize the resistance mechanisms to osimertinib for targeting 
by fourth-generation inhibitors. A new class of inhibitors, designed to target 
a triple mutation thought to confer resistance to fourth-generation EGFR-
TKIs, is also under development.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
 
Element ID Research question 
Description of the technology 
B0001 What is osimertinib? 
A0022 Who manufactures osimertinib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has osimertinib received marketing authorisation? 
Health problem and current use 
A0002 What is NSCLC? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of osimertinib on mortality? 
D0005 How does osimertinib affect symptoms and findings (severity, frequency) of NSCLC? 
D0006 How does osimertinib affect progression (or recurrence) of NSCLC? 
D0011 What is the effect of osimertinib on patients ̕ body functions? 
D0012 What is the effect of osimertinib on generic health-related quality of life? 
D0013 What is the effect of osimertinib on disease-specific quality of life? 
Safety 
C0008 How safe is osimertinib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying osimertinib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of osimertinib? 
A0021 What is the reimbursement status of osimertinib? 
 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Osimertinib/Tagrisso
®
/AZD9291 
 
B0001: What is osimertinib? 
The epidermal growth factor receptor (EGFR), a transmembrane receptor 
with tyrosine kinase activity, regulates cellular proliferation. In a subset of 
non-small cell lung cancers (NSCLC), gatekeeper mutations in the EGFR 
kinase domain induce constitutive activation of the receptor resulting in un-
controlled cell growth. Osimertinib, an irreversible third-generation EGFR 
tyrosine kinase inhibitor (EGFR-TKI), prevents cell cycle progression by se-
lectively targeting both EGFR-TKI-sensitizing mutations and EGFRT790M 
resistance mutations, while sparing wild-type EGFR function. 
Osimertinib is administered as an 80 mg oral tablet taken once daily, with or 
without food, until disease progression or unacceptable toxicity. Patients 
who have difficulty swallowing may disperse the tablet in two ounces of non-
carbonated water [2]. 
Patients with congenital or drug-induced long heart rate-corrected QT 
(QTc) interval, congestive heart failure, or electrolyte abnormalities should 
undergo periodic electrocardiogram (ECG) and electrolyte monitoring. 
Baseline and periodic cardiac monitoring, including left ventricular ejection 
fraction (LVEF) assessment, is required for patients with cardiac risk fac-
tors. Patients with symptoms of keratitis should be referred to an ophthal-
mologist. Dose interruption, reduction (40 mg), or discontinuation may be 
necessary in patients that develop interstitial lung disease (ILD) or pneu-
monitis, prolonged QTc interval, symptomatic congestive heart failure 
(CHF), or intolerance due to adverse events (AEs). Patients should avoid 
concomitant use of strong CYP3A inducers; if this is not possible, they 
should have their osimertinib dose increased to 160 mg when using strong 
CYP3A4 inducers [2].  
 
A0022: Who manufactures osimertinib? 
AstraZeneca  
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Osimertinib is indicated as initial therapy for patients with previously un-
treated epidermal growth factor mutation-positive (EGFRm) advanced 
non-small cell lung cancer (NSCLC) [3].  
third-generation EGFR-
TKI 
80 mg orally once daily 
monitor cardiac and 
keratitis risks; 
 reduce/ interrupt/  
discontinue for safety/ 
tolerability 
previously untreated 
EGFRm-positive 
advanced NSCLC 
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4 Current regulatory status 
A0020: For which indications has osimertinib received marketing authorisa-
tion? 
In November 2015, the US Food and Drug Administration (FDA) granted 
accelerated approval of osimertinib for EGFR-TKI-pre-treated advanced 
EGFRT790M-positive NSCLC along with the companion diagnostic test 
(Cobas
®
 EGFR Mutation Test v2, Roche Molecular Systems) used to detect 
tumour EGFRT790M. Initial approval was based on the objective response 
rate (ORR) reported in two phase II, single-arm, open-label, clinical trials, 
AURA and AURA2 [4-7]. In September 2016, the Cobas
®
 EGFR Mutation 
Test v2 received a label extension for use with plasma samples. In March 
2017, osimertinib was granted full approval based on the results of the con-
firmatory phase III AURA3 trial [5, 8].  
In December 2017, the FDA granted priority review to a supplemental new 
drug application (sNDA) for the use of osimertinib as first-line treatment 
for patients with advanced NSCLC whose tumours have EGFR exon 19 de-
letions (Ex19del) or exon 21 (L858R) substitution mutations as detected by 
an FDA-approved test. In April 2018, osimertinib received approval for this 
indication based on results of the phase III FLAURA trial [3, 9].  
Based on results of the AURA and AURA2 trials, osimertinib received con-
ditional marketing authorisation by the European Medicines Agency (EMA) 
in February 2016, for EGFRT790M-positive NSCLC, irrespective of previ-
ous EGFR-TKI treatment, as determined by a validated diagnostic test on a 
tumour sample or blood-based circulating tumour DNA (ctDNA) [5]. Full 
marketing authorisation was issued for this indication in April 2017, follow-
ing results of the AURA3 trial [10]. In November 2017, the EMA accepted a 
variation to the marketing authorization application (MAA) for osimertinib 
as first-line treatment for EGFR-mutated NSCLC [11]. While osimertinib is 
not approved in Europe for the first-line setting, the Committee for Medici-
nal Products for Human Use (CHMP) adopted a positive opinion recom-
mending a change to the terms of the marketing authorisation of osimertinib 
in April 2018 [12]. 
 
 
 
5 Burden of disease 
A0002: What is NSCLC? 
NSCLC is the most common epithelial lung cancer and accounts for approxi-
mately 80–85% of all lung cancers. Adenocarcinoma, the most frequent histo-
logical type, has a survival rate of approximately 4–6% at five years [13-15]. 
EGFR-mutated tumours are typically characterized by air bronchogram, pleu-
ral retraction, small lesion size, and the absence of fibrosis [16]. Somatic 
EGFR mutations are found in up to 40% of Asian patients and 10–15% of 
Caucasian patients with lung adenocarcinoma [17, 18]. 
FDA: licensed for EGFR-
TKI-pre-treated 
advanced EGFRT790M-
positive NSCLC in 
November 2015 
FDA: licensed first-line 
for advanced EGFR-
mutated NSCLC in April 
2018 
EMA: MAA for first-line 
treatment of EGFR-
mutated NSCLC in 
November 2017; CHMP 
adopted a positive 
opinion in April 2018 
NSCLC accounts for 80–
85% of all lung cancers; 
EGFR-mutations in 15–
20% of 
adenocarcinomas 
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EGFR mutations cluster in the region encoding the adenosine triphosphate-
binding pocket of the kinase domain, exons 18 to 21, inducing constitutive ac-
tivation of the receptor. Approximately 85–90% of all EGFR mutations are 
due to the in-frame exon 19 deletion (Ex19del) (45%) and the exon 21 point 
mutation (L858R) (40–45%), that substitutes arginine for leucine at position 
858 [5, 16]. Commonly referred to as sensitizing mutations, they confer sensi-
tivity to TKIs. While activating EGFR mutations in NSCLC are predictive of 
progression-free survival (PFS) and tumour response, EGFR-TKI-treated pa-
tients inevitably develop resistance and disease progression [16, 19]. Approxi-
mately 50–60% of known acquired resistance to first-line EGFR-TKIs is due 
to the EGFRT790M mutation, where threonine is substituted with methionine 
at position 790 in exon 20, impairing the binding of first-generation TKIs to 
the ATP-kinase binding pocket. Osimertinib, a third generation EGFR-TKI, 
was developed specifically to target the EGFRT790M [20]. Unlike first-
generation EGFR-TKIs that reversibly inhibit EGFR, irreversible third-
generation osimertinib has an acrylamide Michael acceptor that covalently 
bonds the EGFR C797 residue and circumvents the sterically hindered T70M 
substitution, allowing enhanced drug-kinase complex formation [5, 16]. 
 
A0004: What is the natural course of NSCLC? 
Lung cancer typically arises when epithelial cells lining the bronchial tubes 
undergo aberrant cell growth. To facilitate treatment, lung cancer is staged 
from I through IV based on tumour size, and presence or absence of lymph 
node involvement and metastases (TNM). Stage I lung cancer is <3 cm and 
localized to one lobe; stage II has spread to other parts of the lung or lymph 
nodes; stage III may be large or spread to lymph nodes between the lungs; 
and stage IV has metastasized to the adjacent bones, lung, brain, liver or any 
other organ.  
 
A0006: What are the consequences of NSCLC for the society? 
Lung cancer is the second most commonly diagnosed cancer. While the im-
plementation of smoking cessation programs and multidisciplinary treat-
ments have reduced the incidence and mortality, 52–58% of lung cancer pa-
tients present with advanced-stage disease when curative treatment is no 
longer feasible. While demographic analyses suggest that adenocarcinoma 
histology, female gender, older age, non-smoking status, and Asian ethnicity 
are associated with better outcomes, they are surrogate markers for the pres-
ence of activating EGFR mutations (exon 19 deletion, L858R point mutation 
in exon 21) that are strong predictors of EGFR-TKI-responsiveness and 
prognosis [16, 21, 22]. 
 
A0023: How many people belong to the target population? 
Lung cancer is the leading cause of cancer-related death in men and the sec-
ond in women worldwide. The age standardized incidence rate for the Euro-
pean Standard Population was 57.9 per 100,000 persons per year in 2015. In 
Austria, 2,956 men and 1,904 women were diagnosed with lung cancer. It 
was the second most common cancer in men and women (12% of all cancers) 
[23]. Approximately 6.5% of people will be diagnosed with lung cancer dur-
ing their lifetime and approximately one-third of patients with NSCLC have 
a stage III presentation. Assuming this, about 1,620 patients in Austria 
85–90% of EGFR 
mutations are Ex19del 
and L858R; confers 
sensitivity to TKIs 
 
EGFRT790M confers 
acquired resistance to 
first-line EGFR-TKIs  
staged I-IV by 
invasiveness 
metastasizes to bone, 
liver, brain, lymph nodes 
52–58% present with 
advanced cancer; 
relapse and metastasize 
 
activating EGFR 
mutations confer 
favourable prognosis 
4,860 Austrians were 
diagnosed with NSCLC 
in 2015 
 
EGFR-mutated NSCLC 
incidence in Europe: 10–
15% 
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(2015) had stage III NSCLC at the time of diagnosis. EGFR-mutated 
NSCLC accounts for approximately 10–15% of NSCLC patients in Europe, 
30–40% in Asia, and 7–8% in North America [13]; and is diagnosed at a me-
dian age of 64 years (range 26-93) [3, 22]. 
 
A0005: What are the symptoms and the burden of disease or health condi-
tion? 
Many lung cancers are not symptomatic until they have spread. Symptoms 
of NSCLC include incessant cough, bloody sputum, chest pain, wheezing or 
hoarseness, weight loss or loss of appetite, shortness of breath, fatigue, and 
recurrent bronchitis or pneumonia. Lung cancer may metastasize to bone, 
brain, liver or lymph nodes causing pain, headaches, improper balance, sei-
zures, jaundice or lumps near the body’s surface [14].  
 
A0003: What are the known risk factors for NSCLC? 
Overall, the risk of lung cancer increases with age, tobacco use, radiation ex-
posure, air pollution, and occupational exposure to asbestos, arsenic, chro-
mium beryllium, nickel, second-hand smoking and other agents. The risk of 
developing lung cancer is typically tenfold higher in smokers compared to 
lifetime non-smokers [14]. However, the proportion of EGFR-mutated lung 
cancer is 32–64% in never smokers versus 6–33% in smokers; 22–60% in 
women versus 8–37% in men; 30–40% in Asians versus 10–15% in Cauca-
sians; and 66% in those >50 years versus 57.8% in patients <50 years [13, 
22].   
 
A0024: How is NSCLC currently diagnosed according to published guide-
lines and in practice? 
While some lung cancers may be found through screening, most are identi-
fied when they become symptomatic. Following a clinical history and physi-
cal exam, a chest x-ray may be done to identify any abnormal areas in the 
lungs. A computed tomography (CT) scan may show the size, shape and lo-
cation of any lung tumours or enlarged lymph nodes, and guide a needle bi-
opsy if a suspected area is identified. Lung cancer is diagnosed by examin-
ing cells derived through biopsy, cytology or sputum sampling for the pres-
ence of cancer cells.  
NSCLC symptoms: 
cough, chest pain, 
weight loss, shortness of 
breath 
risk factors: non-
smokers, female gender, 
Asian ethnicity, 
increasing age  
diagnosis: x-ray, CT and 
biopsy 
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Several polymerase chain reaction (PCR)-based platforms are available to 
assess tumours for the presence of activating EGFR mutations [20, 24]. Mu-
tation analysis is typically performed on tissue samples from biopsy; howev-
er, circulating tumour cells (CTC) are collected non-invasively through liq-
uid biopsy when tissue samples are inadequate. Circulating tumour DNA 
(ctDNA) analysis is a validated method of liquid biopsy that identifies tu-
mour fragments within plasma. Strategies developed to enhance the sensitiv-
ity of ctDNA analysis include the amplified refractory mutation system 
(ARMS), digital PCR, PCR clamping, denaturing high performance liquid 
chromatography (DHPLC) and next generation sequencing (NGS). Com-
mercially available kits such as the Roche Cobas
®
 EGFR mutation tests (v1 
and v2) and the QIAGEN therascreen EGFR Rotor-Gene Q PCR kit use 
ARMS to detect up to 1–5% of mutant DNA on a background of wild-type 
DNA. Digital droplet PCR (ddPCR) and Beads, Emulsions, Amplification 
and Magnetics (Beads) further increase the sensitivity of detection of mutant 
DNA to a threshold of 0.01–0.03% using a combination of digital PCR and 
flow cytometry. Cancer Personalized Profiling by deep Sequencing (CAPP-
Seq), a NGS-based method, detected ctDNA in 100% of stage II-IV NSCLC 
patients and 50% of stage I patients with 96% specificity for the mutant al-
lele to a threshold of 0.02% [20].  
 
 
 
6 Current treatment 
A0025: How is NSCLC currently managed according to published guide-
lines and in practice? 
Depending on the tumour stage, histology, and the patients’ overall health, 
surgery, radiation therapy and/or platinum-based chemotherapy may be 
used alone or in combination to treat NSCLC. Treatment per NSCLC stages 
involves the following options [25]:  
 Stage I and II NSCLC patients typically undergo surgery to remove 
the cancer. Stage II patients and a subset of patients with stage Ib 
tumours may benefit from postoperative adjuvant chemotherapy.  
 Patients with stage I or II cancers that are not surgical candidates, 
due to co-morbidities or limited lung function, may undergo local ra-
diation therapy.  
 Stage III NSCLC patients are highly heterogeneous and may undergo 
a combination of treatment modalities including chemotherapy and 
radiation and/or surgery depending on the extent and localization of 
disease.  
 Patients with stage IV disease are treated with systemic therapy or a 
symptom-based palliative approach.  
 
In appropriately selected patients, chemotherapy, molecularly targeted ther-
apy, and/or immunotherapy may be used to treat stage III NSCLC [24]: 
 While the optimal chemotherapy regimen for use with concurrent ra-
diotherapy is not known, cisplatin plus etoposide, carboplatin, or vi-
activating EGFR 
mutation status: PCR-
based assessment of 
tissue or blood samples 
 
 
 
 
 
 
 
 
companion diagnostic: 
detects mutant DNA 
versus wild-type at 5% 
sensitivity 
treatment by stage: 
surgery, radiation 
therapy, chemotherapy 
stage III NSCLC 
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norelbine and placlitaxel are commonly used. The combination of 
pemetrexed and cisplatin has also emerged as an option for stage III 
patients with non-squamous histology. 
 The standard dose fractionation regimen of radiotherapy with chemo-
therapy for stage III NSCLC is 60 Gy in 30 daily fractions. Intensity 
modulated radiation therapy is preferred over 3D radiotherapy due to 
the reduced risk for pneumonitis.  
 Patients with ALK translocations benefit from crizotinib, ceritinib, 
alectinib, lorlatinib or brigatinib therapy. First-line therapy for 
ROS1-translocated NSCLC is crizotinib; cabozantinib, ceritinib or 
lorlatinib may be effective for crizotinib-resistant cancers. First-line 
therapy for stage IV patients with BRAF V600E is combination 
dabrafenib plus trametinib.  
 Pembrolizumab, nivolumab, and atezolizumab block PD-L1 on T-
lymphocytes and are used as second-line therapies for advanced 
NSCLC. Durvalumab is the first FDA-approved treatment for stage 
III unresectable NSCLC, but it is not yet approved in Europe [26]. 
 NSCLC patient with genetic alterations in EGFR may benefit from 
TKIs such as first generation erlotinib or gefitinib, or second-
generation afatinib. Third generation TKI osimertinib also targets 
the EGFRT790M mutation associated with acquired resistance to 
EGFR-TKIs. However, osimertinib is not approved in Europe for the 
first-line setting, but the CHMP adopted a positive opinion recom-
mending a change to the terms of the marketing authorisation of 
osimertinib [12]. 
 
 
 
7 Evidence 
A literature search was conducted on 05 April 2018 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “osimertinib”, “tagrisso”, “l01xe35”, “non small cell lung 
cancer”, “NSCLC”, “first line”, “untreated”, and “initial”. The manufactur-
er was also contacted and submitted a reference and a supplemental appen-
dix that had already been identified by systematic literature search [3, 27]. A 
manual search identified five FDA approval documents [2, 9, 26, 28, 29], 
three EMA marketing authorization application notifications [10-12], six 
clinical guidance documents [14, 16, 21, 22, 24, 25], three clinical articles [7, 
30, 31], two statistical documents [15, 25], and two cost editorials [32, 33]. 
Ongoing trials information was found on www.clinicaltrials.gov. 
Overall, 185 references were identified. Included in this reported are:  
 FLAURA [3, 27] 
 AURA3, phase III [8] 
 AURA2, phase II [7] 
 AURA, phase I/II [6, 30, 31] 
targeted therapies 
systematic literature 
search in 5 databases:  
165 hits 
 
 
manual search: 21 
additional references 
overall: 186 references 
included: 4 studies 
Horizon Scanning in Oncology 
14 LBI-HTA | 2018 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [34]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 5 of the Appendix. 
The external validity of the included trials was assessed using the EU-
netHTA guideline on applicability of evidence in the context of a relative ef-
fectiveness assessment of pharmaceuticals, considering the following ele-
ments: population, intervention, comparator, outcomes and setting (Table 4) 
[35]. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [36]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [37]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence, amount of eligible pa-
tients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
 
 
 
 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of  
study results 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
internal and external 
review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
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7.2 Clinical efficacy and safety –  
phase III studies 
FLAURA (NCT02296125) is a multicentre, double-blind, randomised, con-
trolled phase III study involving 556 patient with previously untreated, 
EGFR mutation-positive advanced NSCLC [3]. The study was designed to 
evaluate the safety and efficacy of osimertinib compared to standard of care 
(SoC) EGFR-TKIs gefitinib or erlotinib as initial treatment for locally ad-
vanced or metastatic EGFR-mutated NSCLC. Efficacy analyses were based 
on all randomly assigned patients comprising the intent-to-treat (ITT) popu-
lation. Safety analyses involved all patients who received at least one dose of 
the study drug; all randomly assigned patients received at least one dose of 
the trial treatment.  
Eligible patients were 18 years or older, with untreated locally advanced or 
metastatic NSCLC, and a locally or centrally confirmed EGFR EX19del or 
L858R mutation alone or co-occurring with other EGFR mutations (Cobas
®
 
EGFR Mutation Test or investigational assay at an accredited laboratory). 
Patients with CNS metastases whose condition was neurologically stable 
were eligible. Any previous definitive treatment or glucocorticoid therapy 
must have been completed at least two weeks prior to trial entry. Patients 
were excluded if they had concurrent active malignancy, symptomatic brain 
metastases, spinal cord compression, uncontrolled systemic or gastrointesti-
nal diseases, increased risk of QTc prolongation, arrhythmia or interstitial 
lung disease, concurrent cytochrome P450 inducers or prior systemic or 
EGFR-TKI treatment for advanced NSCLC. Study participants were strati-
fied by EGFR tumour status (EXdel19 or L858R) and race (Asian or non-
Asian).  
Patients were randomised 1:1 to receive osimertinib (80 mg orally, once dai-
ly; n = 279) or SoC EGFR-TKI (250 mg gefitinib; n = 183 or 150 mg erlo-
tinib; n = 94 orally, once daily) until disease progression, unacceptable tox-
icity or patient withdrawal. Dose interruptions, reductions and treatment 
beyond progression were allowed based on investigator-assessed continued 
clinical benefit. A protocol amendment allowed SoC patients to cross over to 
open-label osimertinib after confirmation of disease progression by blinded 
independent central review (BICR) and post-progression documented 
T790M-positive status as determined by local or central plasma or tissue 
testing. The median duration of total treatment exposure was 16.2 months 
(range 0.1–27.4) for patients receiving osimertinib and 11.5 months (range 
0.0–26.2) for those receiving SoC. 
At data cut-off, an event of Response Evaluation Criteria in Solid Tumours 
(RECIST)-defined progression or death had occurred in 136 (49%) of osi-
mertinib patients and 206 (74%) of SoC patients. Approximately 67% of 
osimertinib recipients and 70% of SoC recipients continued treatment be-
yond RECIST-defined progression, while 82 (29% of osimertinib and 129 
[47%] of SoC) patients started subsequent therapy. Of these, 55 SoC patients 
received osimertinib (48 on cross over and seven as second-line therapy out-
side of the trial). The median duration of follow-up for PFS was 15.0 (range 
0.0–25.1) and 9.7 months (range 0.0–26.1) for the osimertinib and SoC 
groups, respectively.  
FLAURA: osimertinib 
versus SoC as initial 
therapy for advanced 
EGFR-mutated NSCLC 
ITT (n = 556): stratified 
by EGFR mutation 
status (EXdel19 or 
L858R) and race (Asian 
or non-Asian) 
80 mg osimertinib 
versus 250 mg gefitinib 
or 150 mg erlotinib 
orally, once daily 
 
median treatment 
exposure: 16.2 months 
of osimertinib versus 
11.5 months of SoC 
death/progression at 
data cut-off: 
osimertinib: 49%  
SoC recipients: 74% 
 
cross over: 48 SoC 
switched to osimertinib 
post-progression 
Horizon Scanning in Oncology 
16 LBI-HTA | 2018 
The primary endpoint of investigator-assessed duration of PFS was evaluat-
ed from randomisation to RECIST-defined progression or death. Secondary 
endpoints reported in the article include the overall survival (OS; time from 
randomisation until all-cause death), objective response rate (ORR; percent-
age of patients with measurable disease with at least one partial [PR] or 
complete response [CR]), duration of response (DOR; time from response 
until progression or death), disease control rate (DCR; percentage of pa-
tients with a best overall response of CR, PR or stable disease [SD] ≥6 
weeks before progression), depth of response (DTOR; change in target-
lesion size from baseline), and safety. Other endpoints not reported in the 
current analysis include patient reported outcomes (PRO; Cancer Therapy 
Satisfaction Questionnaire), health related quality of life (HRQoL; EORTC 
QLQ-C30), disease-related symptoms (HRQoL; EORTC QLQ-LC13), and 
pharmacokinetics. Tumours were assessed according to RECIST version 1.1 
at baseline, every six weeks for 18 months, then every 12 weeks until disease 
progression. Adverse events (AEs) were graded for severity according to the 
National Cancer Institute Common Terminology Criteria version (CTCAE) 
version 4.0.  
The ITT population (n = 556) had a median age of 64 years (range 26–93), 
63% were female, 62% were Asian, 64% were never smokers, 21% had cen-
tral nervous system (CNS) metastases, 63% harboured EX19 del mutations 
and 37% had L858R mutations in EGFR at randomisation. Detailed patient 
characteristics including inclusion- and exclusion criteria can be found in 
Table 5 and study quality is described in Table 6 of the appendix, respec-
tively. Clinical efficacy data are presented in Table 1 and AEs are listed in 
Table 2. 
 
7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of osimertinib on mortality? 
The median OS could not be calculated for either treatment group; survival 
data were immature at the time of data analysis. Approximately 89% (95% 
confidence interval [CI] 85–92%, n = 248) of the osimertinib group and 82% 
(95% CI 77–86%, n = 227) of the SoC group reached 12-month survival. At 
18 months, 83% (95% CI 78–87%, n = 232) of osimertinib patients and 71% 
(95% CI 65–76%, n = 197) of SoC patients achieved survival. At interim 
analysis of OS, a total of 141 patients had died, 58 (21%) of osimertinib re-
cipients and 83 (30%) of SoC recipients (HR for death 0.63, 95% CI 0.45–
0.88; p = 0.007). 
 
D0006: How does osimertinib affect progression (or recurrence) of NSCLC? 
The primary endpoint of median investigator-assessed PFS was 18.9 months 
(95% CI 15.2–21.4) in osimertinib patients versus 10.2 months (95% CI 9.6–
11.1) in SoC patients. The median duration of follow-up for PFS was 15.0 
months (range 0.0–25.1) and 9.7 (range 0.0–26.1) for the osimertinib and 
SoC groups, respectively. Compared with SoC, osimertinib increased PFS as 
determined by BICR (HR for disease progression or death 0.45, 95% CI 
0.36–0.57; p < 0.001).  
primary endpoint: 
investigator-assessed 
PFS 
secondary endpoints: 
OS, ORR, DOR, DCR, 
DTOR, and safety 
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ITT: median age 64 
years, 62% Asian, 21% 
CNS metastases, 63% 
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assessed PFS:  
osimertinib: 18.9 
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The PFS benefit of osimertinib over SoC was demonstrated across all prede-
fined subgroups; a PFS benefit was observed regardless of race (n = 347 
Asians, HR 0.55, 95% CI 0.42–0.72 versus n = 209 non-Asians, HR 0.34, 
95% CI 0.23–0.48) and osimertinib demonstrated a PFS benefit over SoC re-
gardless of EGFR mutation type (n = 349 EX19del, HR 0.43, 95% CI 0.32–
0.56 versus n = 207 L858R, HR 0.51, 95% CI 0.36–0.71). Consistent PFS 
benefit was also observed in the presence or absence of known or treated 
CNS metastases at trial entry (n = 116 CNS metastases, HR 0.47, 95% CI 
0.30–0.74 versus n = 440 no CNS metastases HR 0.46, 95% CI 0.36–0.59) 
and irrespective of the status of known or treated CNS metastases at trial en-
try; CNS progression was observed in 17 patients (6%) in the osimertinib 
group and 42 (15%) in the SoC group.  
 
D0005: How does osimertinib affect symptoms and findings (severity, fre-
quency) of NSCLC? 
The investigator-assessed ORR in the ITT population was 80% (95% CI 75–
85) in the osimertinib group and 76% (95% CI 70–81) in the SoC group re-
cipients (odds ratio [OR] 1.27, 95% CI 0.85–1.90; p = 0.24). Patients without 
CNS metastases at trial entry derived similar clinical benefit from osimer-
tinib than those without (n = 116 CNS metastases, OR 0.5, 95% CI 0.2–1.3; 
p = 0.16 versus n = 440 no CNS metastases, OR 1.6, 95% CI 1.0–2.5; p = 
0.04). The percentage of patients with the best overall response, or DCR, was 
97% (95% CI 94–99) in the osimertinib group versus 92% (95% CI 89–95) in 
the SoC group (OR 2.78, 95% CI 1.25–6.78; p = 0.01). The median best per-
centage change in target lesion size, or DTOR, was -54.7% (range -100.0–
61.9) in osimertinib recipients versus -48.5% (range -100.0–54.1) in SoC re-
cipients.  
The median TTR was 6.1 weeks (95% CI 6.0–6.1) in the osimertinib group 
and 6.1 weeks (95% CI not estimable) the SoC group. Among responders, 
disease progression or death occurred in 106 of 223 (48%) of osimertinib re-
cipients and 158 of 210 (75%) of SoC recipients at the time of data analysis. 
The median DOR was 17.2 months (95% CI 13.8–22.0) in osimertinib pa-
tients and 8.5 months (95% CI 7.3–9.8) in SoC patients. Patients with CNS 
metastases had a median DOR of 13.8 months (95% CI 10.8–20.2) in the 
osimertinib group versus 8.3 months (95% CI 5.5–9.6) in the SoC group.  
 
D0011: What is the effect of osimertinib on patients̕ body functions? 
Osimertinib may cause ILD, pneumonitis, prolonged QT interval, cardio-
myopathy, keratitis and embryo-foetal toxicity [2]. Changes in QTc interval 
were reported in 29 (10%) of osimertinib patients and 13 (5%) of SoC pa-
tients. Cardiac failure was reported in 12 (4%) of patients in the osimertinib 
group and 6 (2%) of patients in the SoC group. Most AEs, ten of 12 osimer-
tinib patients versus five of six SoC patients, were a result of decreased left 
ventricular ejection fraction (LVEF) [27]. ILD and pneumonitis were re-
ported in six (2%) and five (2%) osimertinib patients and 4 (1%) and 2 (1%) 
of SoC patients, respectively [27]. Keratitis was reported in 0.7% of 1142 pa-
tients treated with osimertinib in clinical trials [2]. Osimertinib may cause 
infertility and foetal harm based on its mechanism of action. 
 
consistent PFS benefit: 
across race, EGFR 
mutation type and 
presence/absence of 
CNS metastases 
ORR ITT: 
osimertinib: 80% 
SoC: 76% 
median DOR: 
osimertinib: 17.8 months 
SoC: 8.5 months 
ILD, pneumonitis, 
prolonged QTc interval, 
cardiomyopathy, 
keratitis, infertility and 
foetal toxicity 
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D0012: What is the effect of osimertinib on generic health-related quality of 
life? 
No evidence was reported regarding the effect of osimertinib on generic 
health-related QoL.  
 
D0013: What is the effect of osimertinib on disease-specific quality of life? 
No evidence was reported regarding the effect of osimertinib on disease-
specific QoL.  
 
 
Table 1: Efficacy results of FLAURA [3, 27] 
Descriptive statis-
tics and estimate 
variability 
Treatment group Osimertinib SoC EGFR-TKI 
Number of subjects 279 277 
Progression or death at data cut-off, n (%) 136 (49) 206 (74) 
BICR-assessed median PFS, m (95% CI) 
Investigator-assessed median PFS, m (95% CI) 
Median DOFU for PFS, m (95% CI) 
  PFS, n, m (95% CI), with CNS metastases 
  PFS, n, m (95% CI) without CNS metastases 
  PFS, n, m (95% CI), with exon 19 deletion 
  PFS, n, m (95% CI), with L858R mutation 
17.7 (15.1–21.4) 
18.9 (15.2–21.4) 
15.0 (0.0–25.1) 
n=53; 15.2 (12.1–21.4) 
n= 226; 19.1 (15.2–23.5) 
n= 175; 21.4 (16.5–24.3) 
n=104; 14.4 (11.1–18.9) 
9.7 (8.5–11.0) 
10.2 (9.6–11.1) 
9.7 (0.0–26.1) 
n=63; 9.6 (7.0–12.4) 
n= 214;10.9 (9.6–12.3) 
n=174; 11.0 (9.7–12.6) 
n=103; 9.5 (8.1–11.0) 
Investigator-assessed ORR, % (95% CI) 
  ORR, n, % (95% CI) with CNS metastases 
  ORR, n, % (95% CI) without CNS metastases 
80 (75–85) 
n=53; 76 (62–86) 
n=226; 81 (75–86) 
76 (70–81) 
n=63; 88 (75–93) 
n=214; 73 (66–79) 
DCR, % (95% CI) 97 (94–99) 92 (89–95) 
DTOR, % (range) -54.7 (-100–61.9) -48.5 (-100–54.1) 
Response, n (%) 
  CR 
  PR 
  SD ≥6 weeks 
  Progression 
  Death 
  NE 
 
7 (3) 
216 (77) 
47 (17) 
3 (1) 
0 (0) 
6 (2) 
 
4 (1) 
206 (74) 
46 (17) 
14 (5) 
5 (2) 
7 (3) 
Investigator-assessed median DOR, m (95% CI) 
Range 
  DOR, n, m (range), with CNS metastases 
  DOR, n, m (range), without CNS metastases 
  DOR continued response at 12 m, n, (95% CI) 
  DOR continued response at 18 m, n, (95% CI) 
  DOR continued response at 24 m, n, (95% CI) 
17.2 (13.8–22.0)  
0.0–23.8 
n=40; 13,8 (10.8-20.2) 
n=183; 17.6 (13.8-23.0) 
64 (58–70) 
49 (41–56) 
NE (NE–NE) 
8.5 (7.3–9.8) 
0.0–24.9 
n=54; 8.3 (5.5-9.6) 
n=156; 9.6 (8.1-11.2) 
37 (31–44) 
19 (13–26) 
5 (1–16) 
Median TTR 
 Weeks median (95% CI) 
  ≤6 weeks after first dose, n/N (%) 
  ≤12 weeks after first dose, n/N (%) 
  ≤18 weeks after first dose, n/N (%) 
 
6.1 (6.0–6.1) 
154/223 (69) 
193/223 (87) 
199/223 (89) 
 
6.1 (NE–NE) 
148/210 (70) 
180/210 (86) 
196/210 (93) 
Median OS, m (95% CI) 
  Survival at 6 m, %, (95% CI) 
  Survival at 12 m, %, (95% CI) 
  Survival at 18 m, %, (95% CI) 
NE (NE–NE) 
98 (96–99) 
89 (85–92) 
83 (78–87) 
NE (NE–NE) 
93 (90–96) 
82 (77–86) 
71 (65–76) 
Death n (%) 58 (21) 83 (30) 
 QoL NA NA 
 
 
generic health-related 
QoL: no evidence 
 
disease-specific QoL: no 
evidence 
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Effect estimate per 
comparison 
 
Comparison groups Osimertinib versus 
SoC EGFR-TKI 
Investigator-assessed PFS 
(primary endpoint) 
HR 0.46 
95% CI 0.37–0.57 
Log-rank test p-value <0.001 
BICR-assessed PFS  
(primary endpoint) 
HR 0.45 
95% CI 0.36–0.57 
Log-rank test p-value <0.001  
Investigator-assessed PFS 
(subgroup analysis) 
HR Asians (n=347) ver-
sus non-Asians (n=209) 
0.55 versus 0.34 
95% CI 
0.42–0.72 versus 
0.23-0.48 
Log-rank test p-value <0.001  
 
 
Investigator-assessed PFS 
(subgroup analysis) 
HR with CNS metastases 
(n=116) versus without 
(n=440) 
0.47 versus 0.46 
95% CI 0.30–0.74 versus 
0.36–0.59 
Log-rank test p-value <0.001  
Investigator-assessed PFS 
(subgroup analysis) 
HR EX19del (n=349) ver-
sus L858R (n=207) mu-
tation 
0.43 versus 0.51 
95% CI  0.32–0.56 versus 
0.36–0.71 
Log-rank test p-value <0.001  
ORR, all patients OR 1.27 
95% CI 0.85–1.90 
Log-rank test p-value 0.24 
ORR  
(subgroup analysis) 
OR with CNS metastases 
versus without 0.5 versus 1.6 
95% CI 0.2–1.3 versus 1.0–2.5 
Log-rank test p-value 0.16 and 0.04 
DCR, all patients OR 2.78 
95% CI 1.25–6.78 
Log-rank test p-value 0.01 
Death, all patients HR 0.63 
95% CI 0.45–0.88 
Log-rank test p-value 0.007 
Abbreviations: BICR = blinded independent central review; CI = confidence interval; CNS = central nervous system; CR = complete re-
sponse; DCR = disease-control rate; DOR = duration of response; DOFU = duration of follow-up; DTOR = depth of response; EGFR = 
epidermal growth factor receptor; m = months; n = number; N = total number; NA = not available; NE = not evaluable; NR = not 
reached; OR = odds ratio; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; QoL = quality of life; 
PR = partial response; SD = stable disease; TTR = time to response 
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7.2.2 Safety 
 
C0008: How safe is osimertinib in relation to the comparator(s)? 
The most frequent investigator-assessed AEs reported in the osimertinib 
group of the safety population (n = 279) were rash, diarrhoea, dry skin, 
paronchia, stomatitis, decreased appetite, pruritus, AST and ALT elevation 
[27]. Grade ≥3 AEs were observed in 95 (34%) of osimertinib patients and 
125 (45%) of SoC patients [3]. The most common AEs of grade ≥3 severity 
in the osimertinib group were decreased appetite (3%), pneumonia (2%), di-
arrhoea (2%) and prolonged QTc (2%) [27]. 
Cardiac effects were reported in a higher percentage of osimertinib patients 
than SoC patients (10% versus 5%, respectively). Cardiac AEs were predom-
inantly of grade 1 (4%) or 2 (4%) for osimertinib recipients versus 3% and 
1% for SoC recipients [3]. Cardiac failure was reported in 12 (4%) patients 
of the osimertinib group and six (2%) of the SoC group. A decrease in LVEF 
occurred in ten of 12 osimertinib patients and five of six SoC patients. Pro-
longed QTc interval was reported in 28 (10%) patients of the osimertinib 
group and in eleven 11 (4%) patients of the SoC group; one SoC patient ex-
perienced arrhythmia. AEs of ILD were observed in eleven (4%) patients of 
the osimertinib group and in six (2%) patients of the SoC group. In the osi-
mertinib group, seven of eleven patients recovered while the remaining four 
patients were recovering [3]. No fatal cases of torsades des pointes, pro-
longed QT interval, ILD, or pneumonitis occurred in either treatment group 
[3]. 
Serious adverse events (SAEs) were reported in 60 (22%) of the osimertinib 
group patients and in 70 (25%) patients of the SoC group. One osimertinib 
recipient had a SAE of prolonged QTc interval. SAEs of ILD occurred in six 
patients in the osimertinib group and four patients in the SoC group. Six 
(2%) of osimertinib patients experienced a fatal AE involving pneumonia, 
respiratory tract infection, cerebral infarction, myocardial infarction, pul-
monary embolism and intestinal ischemia while ten (4%) of SoC patients 
died due to sepsis (n = 2), pneumonia (n = 1), endocarditis (n = 1), cogni-
tive disorder and pneumonia (n = 1), peripheral-artery occlusion (n = 1), 
dyspnoea (n = 1), haemoptysis (n = 1), diarrhoea (n = 1) and death not oth-
erwise specified (n = 1).  
 
C0002: Are the harms related to dosage or frequency of applying 
osimertinib? 
Osimertinib was associated with fewer AEs resulting in permanent 
discontinuation than SoC [37 patients (13%) versus 49 (18%), respectively]. 
The frequency of AE-related dose interruption (25% for osimertinib versus 
24% for SoC) and reduction (4% versus 5%, respectively) were similar 
between groups. The most frequently reported AEs leading to dose 
interruption in osimertinib recipients were QT prolongation (n = 8), 
decreased appetite (n = 7), diarrhoea (n = 7) and pneumonia (n = 5). QT 
prolongation (n = 5) and skin disorders (n = 10) were the leading causes of 
dose reductions in osimertinib patients [27].  
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C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of osimertinib? 
Osimertinib should be withheld in patients who present with worsening res-
piratory symptoms indicative of ILD. Clinical trials did not enrol patients 
with baseline QTc >470 msec. Patients with congenital long QTc syndrome, 
congestive heart failure, electrolyte abnormalities, or those taking medica-
tions that prolong the QTc interval should undergo periodic EGC and elec-
trolyte monitoring. Cardiac monitoring and LVEF assessment should be 
conducted in patients with cardiac risk factors and those who develop cardi-
ac symptoms during treatment. Patients who develop symptoms of keratitis 
should be referred to an ophthalmologist. Osimertinib may cause foetal 
harm; females are advised to use effective contraception during treatment 
and for six weeks after the final dose. Males with female partners are advised 
to use effective contraception for four months following their final dose. The 
safety and effectiveness of osimertinib have not been established in paediat-
ric patients. No dose adjustment is recommended for patients with renal or 
hepatic impairment [2].  
Table 2: Most frequent adverse events of FLAURA [3] 
Adverse Event (according  
to CTCAE version 4.0) 
Osimertinib 
(n = 279) 
SoC EGFR-TKI 
(n = 277) 
15% in either Arm 
Any Grade 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any Grade  
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any AE 273 (98) 83 (30) 6 (2) 271 (98) 103 (37) 11 (4) 
Rash or acne 161 (58) 3 (1) 0 (0) 216 (78) 19 (7) 0 (0) 
Diarrhoea 161 (58) 6 (2) 0 (0) 151 (57) 6 (2) 0 (0) 
Dry skin 100 (36) 1 (<1) 0 (0) 100 (36) 3 (1) 0 (0) 
Paronychia 97 (35) 1 (<1) 0 (0) 91 (33) 2 (1) 0 (0) 
Stomatitis 80 (29) 1 (<1) 1 (<1) 56 (20) 1 (<1) 0 (0) 
Decreased appetite 56 (20) 7 (3) 0 (0) 52 (19) 5 (2) 0 (0) 
Pruritus 48 (17) 1 (<1) 0 (0) 43 (16) 0 (0) 0 (0) 
Cough 46 (16) 0 (0) 0 (0) 42 (15) 1 (<1) 0 (0) 
Constipation 42 (15) 0 (0) 0 (0) 35 (13) 0 (0) 0 (0) 
Nausea 39 (14) 0 (0) 0 (0) 52 (19) 0 (0) 0 (0) 
Fatigue 38 (14) 2(1) 0 (0) 33 (12) 2 (1) 0 (0) 
Dyspnoea 35 (13) 1 (<1) 0 (0) 20 (7) 3 (1) 0 (0) 
Anaemia 34 (12) 3 (1) 0 (0) 25 (9) 3(1) 0 (0) 
Headache 33 (12) 1 (<1) 0 (0) 19 (7) 0 (0) 0 (0) 
Vomiting 31 (11) 0 (0) 0 (0) 29 (10) 4 (1) 0 (0) 
Upper RTI 28 (10) 0 (0) 0 (0) 18 (6) 0 (0) 0 (0) 
Pyrexia 28 (10) 0 (0) 0 (0) 11 (4) 1 (<1) 0 (0) 
Prolonged QT interval on 
ECG 28 (10) 5 (2) 1 (<1) 11 (4) 2 (1) 0 (0) 
AST elevation 26 (9) 2 (1) 0 (0) 68 (25) 12 (4) 0 (0) 
Alopecia 20 (7) 0 (0) 0 (0) 35 (13) 0 (0) 0 (0) 
ALT elevation 18 (6) 1 (<1) 0 (0) 75 (27) 21 (8) 4 (1) 
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = common 
terminology for cancer adverse events; ECG = electrocardiogram; RTI = respiratory tract infection; SoC = standard of care 
susceptibles: monitor 
those with respiratory 
symptoms, long QTc, 
cardiac risk factors, 
keratitis 
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7.3 Clinical effectiveness and safety –  
further studies 
AURA3 (NCT02151981) is an ongoing multicentre, randomised, open-label, 
comparative, phase III study to evaluate osimertinib versus SoC platinum-
based chemotherapy in 419 patients with locally advanced or metastatic 
NSCLC, who harbour a T790M and have progressed on previous EGFR-
TKIs [8]. Patients were stratified by Asian or non-Asian race, and randomly 
assigned 2:1 to receive either oral osimertinib (80 mg once daily) or intrave-
nous pemetrexed (500 mg/m
2
 of body-surface area) plus either carboplatin 
(target area under the curve, 5 [AUC5]) or cisplatin (75 mg/m
2
) every three 
weeks for up to six cycles; maintenance pemetrexed was allowed. Patients 
were treated until disease progression, unacceptable toxicity or patient 
withdrawal. Both cross-over to osimertinib following progression and treat-
ment beyond RECIST-defined progression were allowed based on investiga-
tor-assessed continued clinical benefit. The primary endpoint was investiga-
tor-assessed PFS; secondary endpoints included investigator-assessed ORR, 
DOR, DCR, tumour shrinkage, OS, PROs and safety. Tumours were as-
sessed according to RECIST version 1.1 at baseline, every six weeks until 
disease progression up to 19 months. AEs were graded according to the 
CTCAE version 4.0.  
At a median follow-up of 8.3 months, osimertinib patients demonstrated a 
longer median PFS than chemotherapy patients (10.1 months versus 4.4 
months; HR 0.30, 95% CI 0.23–0.41; p < 0.001). At 12 months, approximate-
ly 44% (95% CI 37–51) of osimertinib patients and 10% (95% CI 5–17) of 
chemotherapy patients were still progression-free. The PFS benefit of osi-
mertinib over chemotherapy was observed across all predefined subgroups, 
including patients with CNS metastases (median PFS 8.5 months versus 4.2 
months; HR 0.32, 95% CI 0.21–0.40; p < 0.5); EGFR Ex19del mutation (HR 
0.34, 95% CI 0.24–0.46; p < 0.5); EGFR L858R mutation (HR 0.46, 95% CI 
0.30–0.71; p < 0.5); Asian patients (HR 0.32, 95% CI 0.24–0.44; p < 0.5); 
and non-Asian patients (HR 0.48, 95% CI 0.32–0.75; p < 0.5). Median PFS 
among EGFR T790M-positive patients was 8.2 months for osimertinib recip-
ients versus 4.2 months for chemotherapy recipients (HR 0.42, 95% CI 0.29–
0.61; p < 0.5). Osimertinib treatment was associated with better ORR com-
pared to chemotherapy (71% [95% CI 65–76] versus 31% [95% CI 24–40]; 
OR 5.43, 95% CI 3.47–8.48; p < 0.001). The ORR benefit of osimertinib over 
chemotherapy was reported on both tumour and plasma analyses (89 of 116 
patients [77%] versus 22 of 56 patients [39%]; OR 4.96, 95% CI 2.49–10.15; p 
< 0.001). The median DOR was 9.7 months (95% CI 8.3–11.6) for osimer-
tinib versus 4.1 months (95% CI 3.0–5.6) for chemotherapy. While OS data 
were not mature, 31 (13%) of osimertinib patients and 26 (19%) of chemo-
therapy patients had died at interim analysis.  
The proportion of patients with grade ≥3 AEs was lower with osimertinib 
(23%) than with platinum chemotherapy (47%). In the osimertinib group, 
the most commonly reported AEs were diarrhoea (41%), rash (34%), dry 
skin (23%) and paronychia (22%). ILD-like AEs and prolonged QT interval 
were reported in ten (4%) and ten (4%) of osimertinib recipients and one 
(1%) and one (1%) of chemotherapy patients, respectively. Osimertinib lead 
to fewer permanent discontinuations than chemotherapy (19 [7%] versus 14 
[10%] of patients, respectively). Fatal AEs were reported in four patients in 
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the osimertinib group as a result of respiratory failure (n = 2), pneumonitis 
(n = 1), and ischemic stroke (n = 1).  
AURA2 (NCT02094261) is a multicentre, open-label, single-arm phase II 
study to assess the safety and efficacy of osimertinib in 210 EGFR T790M-
positive advanced NSCLC patients with progression following previous 
EGFR-TKI therapy [7]. Patients received oral osimertinib (80 mg once dai-
ly) and could continue beyond RECIST-defined progression based on inves-
tigator-assessed continued clinical benefit. The primary endpoint was BICR-
assessed ORR; secondary endpoints included PFS, DOR, DCR, tumour 
shrinkage, OS, QoL, QTcF interval change after multiple dosing, pharma-
cokinetics and safety. Tumours were assessed according to RECIST version 
1.1 at baseline, every six weeks until disease progression up to 11 months. 
Adverse events (AEs) were graded according to the CTCAE version 4.0.  
At a median follow-up of 13.0 months, 140 (70%, 95% CI 64–77) of 199 eval-
uable patients achieved an objective response by BICR; CR was confirmed 
in six (3%) of patients and PR was observed in 134 (67%) of patients. The 
ORR was consistent across subgroups, including patients with CNS metasta-
ses. The DCR was 182 of 199 patients (92%, 95% CI 87–95). The median 
DOR was 11.4 months (95% CI 9.0–not estimable), and 48% (95% CI 39–57) 
maintained response at 12 months. Tumour shrinkage was observed in 186 
of 198 (94%) patients. The mean best percentage change in target lesion size 
from baseline was -52%. The median BIRC-assessed PFS was 9.9 months 
(95% CI 8.5–12.3); and PFS at 12 months was 44%. The PFS benefit of osi-
mertinib was consistent across subgroups, including presence or absence of 
CNS metastases, Asian or non-Asian race, EGFR T790M co-occurring with 
EX19del versus L848R. At interim analysis, 44 (21%) of patients had died 
and OS data was not mature. Approximately 75% of patients on treatment 
improved or remained stable in their symptoms of lung cancer (QLQ-LC13; 
n = 85) and in the functioning domains of the QLQ-C30 (n = 90).  
The most common grade ≥3 adverse events were pulmonary embolism (3%), 
prolonged QTc (2%), decreased neutrophil count (2%), anaemia (1%), dysp-
noea (1%), hyponatraemia (1%) increased ALT (1%) and thrombocytopenia 
(1%). Approximately 5% of patients discontinued osimertinib due to AEs. 
Serious AEs were reported in 52 (25%) of patients, 11 (5%) of which investi-
gators assessed as treatment-related. Seven deaths resulted from AEs involv-
ing pneumonia (n = 2), pneumonia aspiration (n = 1), rectal haemorrhage 
(n = 1), dyspnoea (n = 1), failure to thrive (n = 1), and ILD (n = 1). Inves-
tigators assessed the ILD as the only treatment-related fatality.   
AURA (NCT01802632) is a multicentre, open-label, phase I/II study to as-
sess the safety, efficacy and tolerability of osimertinib in 253 patients with 
advanced EGFR-mutated NSCLC in whom resistance to treatment with 
EGFR-TKIs had developed [6]. The study included 31 patients in dose-
escalation cohorts and 222 patients in five dose-expansion cohorts. Patients 
in the dose-escalation cohorts received a single dose of osimertinib followed 
by a pharmacokinetic evaluation period; after seven days they received the 
same dose daily for the remainder of the study. The first dose tested was 20 
mg daily each subsequent dose cohort represented a 100% increase from the 
previous dose. If clinical activity was observed in an escalation cohort, a 
dose-expansion cohort was initiated where daily continuous dosing com-
menced with pharmacokinetic assessments. At data cut-off, enrolment into 
additional cohorts, including patients that had not received prior treatment, 
and phase II extension were ongoing [30].  
AURA2: efficacy and 
safety of osimertinib for 
EGFRT790M-mutated 
advanced NSCLC with 
progression following 
EGFR-TKI therapy 
BICR-assessed ORR at 13 
months: 70% 
 
DCR: 92% 
 
median DOR: 11.4 
months 
 
median PFS: 9.9 months 
 
OS: data not mature 
 
symptoms: 75% were 
stable or improved 
common treatment-
related grade ≥3 AEs: 
prolonged QTc, 
neutropenia, and 
thrombocytopenia  
 
AURA: safety, efficacy 
and tolerability of 
osimertinib for 
EGFRT790M-mutated 
advanced NSCLC with 
resistance to EGFR-TKIs 
 
dose-escalation cohort: 
no defined maximum 
tolerated dose 
 
Horizon Scanning in Oncology 
24 LBI-HTA | 2018 
In the dose-escalation cohort where patients received osimertinib (dose 
range 20–240 mg per dose, once daily), no dose-limiting toxicities occurred 
at any dose level and the maximum tolerated dose could not be defined. In 
the expansion cohorts, all patients underwent tumour assessment for EG-
FRT790M status and 138 (62%) were positive for this mutation. A con-
firmed objective response was found in 123 (51%; 95% CI 45–58) of the 239 
evaluable patients; 85% showed durable response of ≥6 months. Among 127 
patients with centrally confirmed EGFR T790M, the response rate was 61% 
(95% CI 52–70) while the response rate among 61 patients without EGFR 
T790M mutations was 21% (CI 12–24). The median PFS was 9.6 months 
(95% CI 8.3–not estimable) in EGFR T790M-positive patients and 2.8 
months (95% CI 2.1–4.3) in EGFR T790M-negative patients. The most fre-
quent AEs were diarrhoea (47%), rash (40%), nausea and decreased appetite 
(21%); of these, diarrhoea and rash were assessed as dose dependent. Treat-
ment-related serious AEs were observed in 6% of patients involving ILD 
leading to discontinuation of treatment. Based on clinical activity and safety 
data, the 80 mg once daily dose was selected for further investigation.  
Preliminary results from the extension cohort of AURA were presented in a 
pre-planned pooled analysis with the phase II AURA2 study including 411 
EGFR T790M-positive patients. In AURA phase I, investigator-assessed 
ORR was 71% (95% CI 57–82), median DOR was 9.6 months (95% CI 7.7–
15.6) and median PFS was 9.7 months (95% CI 8.3–13.6). In the AURA 
pooled phase II, ORR was 66% (95% CI 61–71), median DOR was 12.5 
months (95% CI 11.1–not estimable), and median PFS was 11.0 months 
(95% CI 9.6–12.4). The AURA pooled phase II results confirmed the find-
ings of AURA phase I [31].  
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of osimertinib? 
In Austria, osimertinib is available as 80 mg, oval tablets in 30-tablet bottles. 
One bottle of 30 osimertinib (Tagrisso
®
) tablets (80 mg) is available for € 
6,132.50 (ex-factory price) [33]. At the recommended dose of 80 mg per day, 
a median duration of treatment exposure of 16 months of osimertinib treat-
ment would cost approximately € 98,120.00. Since osimertinib is indicated 
for EGFR-mutated NSCLC with an incidence of 10–15% in Europe and 
4,860 Austrians are diagnosed with NSCLC, osimertinib would cost between 
€ 35,764,740.00–53,647,110.00 annually with an additional cost of approxi-
mately £ 189.05 (~ € 165.00) per Cobas® EGFR Mutation Test v2 [32]. 
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9 Ongoing research 
Several studies are ongoing to investigate osimertinib as monotherapy or in 
combination with other targeted therapies or immunotherapies to treat vari-
ous stages of NSCLC. In May 2018, searches of www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu using the search terms “osimertinib” and “non-
small cell lung cancer” yielded 60 other registered studies (five phase III, 
twenty phase II, nine phase I/II, sixteen phase I, and ten observational, fea-
sibility or real-world treatment studies). Most studies were industry-
sponsored or conducted in collaboration with industry. 
Selected recently completed and ongoing phase III studies evaluating osi-
mertinib in patients with advanced EGFR-mutated NSCLC previously 
treated with EGFR-TKIs as third-line therapy, in combination with durval-
umab (MEDI4736) (CAURAL), following tumour resection with or without 
adjuvant chemotherapy (ADAURA), for the treatment of brain metastases 
(APOLLO), and in a real world setting (ASTRIS): 
 NCT02959749: is a phase II/III, randomised, open-label, interven-
tional trial to compare the efficacy and toxicity of osimertinib or 
docetaxel-bevacizumab as third-line therapy in patients with locally 
advanced or metastatic EGFR T790M-mutaed NSCLC. Estimated 
study completion date is December 2017. 
 NCT02454933: CAURAL is a phase III, multicentre, randomised, 
open-label study to assess the safety and efficacy of osimertinib in 
combination with the anti-PD-L1 monoclonal antibody durval-
umab (MEDI4736) versus osimertinib monotherapy in patients 
with locally advanced or metastatic EGFR T790M-positive NSCLC 
who have received prior EGFR-TKI therapy. Estimated study com-
pletion date is March 2018.  
 NCT02474355: ASTRIS is a phase III, multicentre, real world 
treatment study to determine the efficacy and safety of osimertinib 
in a real world setting in adults with advanced EGFR T790M-
positive NSCLC who have received prior EGFR-TKI therapy. The 
study will close in participating countries following national reim-
bursement or within 18 months after the last patient enrolment in 
the event national reimbursement is not granted following a rea-
sonable time after market license approval. Estimated study com-
pletion date is April 2019. 
 NCT02972333: APOLLO is a phase III, multicentre, single-arm, 
open-label study to investigate the safety and efficacy of osimertinib 
in brain metastases from patients with EGFR T790M-positive 
NSCLC who have received prior EGFR-TKI therapy. Estimated 
study completion date is December 2019.  
 NCT02511106: ADAURA plus is a phase III, multicentre, random-
ised, double-blind, placebo-controlled trial to evaluate the safety 
and efficacy of osimertinib versus placebo in patients with EGFR-
mutated stage IB-IIIA NSCLC following complete tumour resec-
tion with or without adjuvant chemotherapy. Estimated study com-
pletion date is November 2021. 
60 registered studies 
5 phase III studies 
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In addition, osimertinib is currently under investigation as a combination 
therapeutic with targeted agents. The TATTON trial (NCT02143466) will 
evaluate osimertinib in combination with the anti-PD-L1 monoclonal anti-
body durvalumab, or with MET inhibitor, AZD6094, or with MEK1/2 inhib-
itor, selumetinib, (AZD6244, ARRY-142886) in patients with advanced 
EGFR-mutated NSCLC. However, CAURAL and phase I TATTON were 
suspended when patients taking combination osimertinib with durvalumab 
experienced an increase in ILD [38]. Other combinations with anti-
angiogenic agents or anti-EGFR monoclonal antibodies such as ramu-
cirumab or necitumumab are under investigation (NCT02789345). A phase 
Ib trial is ongoing to evaluate the safety and tolerability of osimertinib and 
navitoxclax (ABT-263), a BCL-2 inhibitor that enhances the apoptotic re-
sponse in late resistant t790M cells and sensitivity to EGFR inhibition [5].  
 
 
 
10 Discussion 
In November 2015, the FDA granted accelerated approval of osimertinib for 
EGFR-TKI-pre-treated advanced EGFRT790M-positive NSCLC along with 
a companion diagnostic test, Cobas
®
 EGFR Mutation Test v2.. Osimertinib 
received full approval in March 2017 when phase II results from AURA [6, 
30, 31] and AURA2 [7] were confirmed in the phase III AURA3 trial [8]. 
Following the phase III FLAURA trial in April 2018 [3], osimertinib was 
approved as first-line treatment for advanced NSCLC with EGFR Ex19del 
or L858R substitution mutations as detected by an FDA-approved test [9]. 
In April 2017, osimertinib received marketing authorisation by the EMA for 
the treatment of EGFRT790M-positive NSCLC, irrespective EGFR-TKI 
pre-treatment, as determined by a validated tumour sample or blood-based 
ctDNA [10]. While osimertinib is not approved in Europe for the first-line 
setting, the CHMP adopted a positive opinion recommending a change to 
the terms of the marketing authorisation of osimertinib in April 2018 [12]. 
First-line FDA-approval of osimertinib was based on the interim results of 
FLAURA, a randomised, double-blind, controlled trial comparing the safety 
and efficacy of osimertinib (80 mg once daily) versus SoC EGFR-TKIs, ge-
fitinib or erlotinib (250 mg and 150 mg once daily, respectively), in 556 un-
treated patients with advanced EGFR-mutated NSCLC [3]. Compared with 
SoC EGFR-TKIs, osimertinib increased median PFS by 8.7 months, and 
lowered the risk of disease progression or death by 54%. The PFS benefit 
was consistent across subgroups regardless of Asian or non-Asian race, 
Ex19del or L858R EGFR subtype, and presence or absence of CNS metasta-
ses. While the ORR was similar between osimertinib and SoC groups (80% 
versus 76%, respectively), osimertinib conferred a longer DOR than SoC 
(17.2 months versus 8.5 months). OS data was immature at interim analysis; 
however, 83% of osimertinib patients and 71% of SoC patients achieved 18-
month survival.  
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The most frequently reported AEs in osimertinib patients were rash, diar-
rhoea, dry skin, paronchia, stomatitis, decreased appetite, pruritis, AST and 
ALT elevation. Grade ≥3 AEs were less common in the osimertinib group 
compared to SoC (34% versus 45%); however, decreased appetite (3%), 
pneumonia (2%), diarrhoea (2%), and prolonged QTc (2%) were most com-
mon. Cardiac and lung effects occurred more frequently in osimertinib re-
cipients than SoC recipients (10% and 4% versus 5% and 2%, respectively); 
notably cardiac failure (4%), prolonged QTc interval (10%), and ILD (4%). 
Fatal AEs occurred in six osimertinib patients due to pneumonia, respirato-
ry tract infection, cerebral infarction, myocardial infarction, pulmonary em-
bolism and intestinal ischemia. While the frequency of AE-related dose in-
terruption and reduction were similar between groups (25% and 4% versus 
24% and 5%, respectively), fewer osimertinib patients discontinued due to 
AEs (13% versus 18%). QT prolongation, decreased appetite, diarrhoea, and 
pneumonia were the most common causes of osimertinib dose interruption.  
Results of the FLAURA study hold some limitations. Follow-up is insuffi-
cient to evaluate OS and long-term safety, and no evidence was reported re-
garding the effect of osimertinib on generic or disease specific QoL. Mature 
OS data and QoL measures are needed to ensure patients achieve a clinically 
relevant benefit over time despite favourable tolerability. In addition, 
NSCLC patients with brain metastases typically have a worse prognosis than 
those without; although early-generation EGFR-TKIs demonstrate better 
CNS efficacy than chemotherapy, many patients progress. While the fre-
quency of CNS progression at interim analysis was less than that observed in 
the SoC EGFR-TKI group, some cases of asymptomatic progression may 
have been undetected as only patients with brain metastases were routinely 
scanned. The ARCHER 1050 trial recently showed a superior median PFS 
with dacomitinib over gefitinib in patients with previously untreated EGFR-
mutated advanced NSCLC but patients with brain metastases were excluded 
from the study.  
The overall generalizability of FLAURA results are fairly good in that the 
study population demonstrated demographic and clinical characteristics 
representative of the global population of patients with EGFR-mutated ad-
vanced NSCLC. However, afatinib, now available for EGFR mutation-
positive NSCLC, received FDA-approval as first-line treatment for NSCLC 
patients whose tumours have non-resistant EGFR mutations as detected by 
an FDA-approved test, including L861Q, G719X and S768I in January 2018 
[39]. Approval was based on pooled analysis of phase II LUX-Lung 2, and 
phase III LUX-Lung 3 and LUX-Lung 6 trials demonstrating the activity of 
afatinib in non-resistant mutations based on ORR, DOR, DCR, PFS and 
OS. Afatinib was initially approved in 2013 for NSCLC with EGFR Ex19del 
or L858R mutations as detected by an FDA-approved test. Therefore, the 
second-generation irreversible EGFR-TKI, afatinib may have been a suita-
ble comparator for irreversible osimertinib compared to first-generation re-
versible gefitinib and erlotinib. However, afatinib irreversibly inhibits wild-
type EGFR expressed in skin and the gastrointestinal tract causing dose-
limiting rash and diarrhoea, so it is unlikely that patients would tolerate 
doses sufficient to overcome T790M-mediated resistance [4]. 
FLAURA is a phase III trial with some methodological limitations. There is 
no risk of bias in the generation of randomisation sequence or allocation 
concealment. Patients were randomly assigned 1:1 to osimertinib or SoC us-
ing an interactive voice/web-based response system [40]. Patients, physi-
cians and outcome assessors were blinded as patients received active osimer-
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tinib plus comparator-matching placebo or active comparator plus osimer-
tinib-matching placebo. Active and placebo tablets were identical and pre-
sented in the same packaging to ensure blinding. Selective outcome report-
ing is unlikely as all outcomes were reported as specified in the clinical pro-
tocol. The risk of bias may be increased by industry involvement in funding, 
study design, data collection, analysis and interpretation as well as due to 
cross over (48 patients switched to osimertinib).  
Given the non-curative treatment setting of osimertinib and the statistically 
significant primary endpoint PFS, we applied Form 2b of the ESMO-MCBS 
in order to assess whether osimertinib satisfies the criteria for a “meaningful 
clinical benefit” (score 4 or 5). Both the original as well as the adapted ver-
sion of the MCBS were applied. The application of the ESMO-MCBS to the 
FLAURA study resulted in a grade 3 in both the original and the adapted 
version of the ESMO-MCBS, respectively. Therefore, osimertinib leads to no 
“meaningful clinical benefit” with the original scale or with the adapted 
framework. 
Mechanisms of resistance to osimertinib have already been identified in pa-
tients with T790M-positive NSCLC after EGFR-TKI therapy, including ac-
quired EGFR mutations C797S, L844V, and L718Q, MET and HER2 ampli-
fication, constitutive ERK activation, and small-cell transformation [5]. 
However, mechanisms of resistance to first-line osimertinib therapy remain 
to be fully characterized. No cases of acquired T790M mutation were ob-
served in the nine patients with previously untreated EGFR-mutated 
NSCLC who received osimertinib in phase I of the AURA trial. Molecular 
analysis of tissue-based and post-progression plasma samples from 
FLAURA study participants may allow greater insight into the mechanisms 
of resistance [3].  
The clinical efficacy and safety data from FLAURA are consistent with data 
from previous studies showing osimertinib holds high specificity for T790M 
mutation-positive advanced NSCLC and improves PFS, ORR and DOR 
with acceptable tolerability [3, 6-8, 30, 31]. Osimertinib was evaluated as ini-
tial EGFR-TKI therapy in FLAURA, while AURA3, AURA2 and AURA 
evaluated osimertinib in patients with EGFR-mutated NSCLC who had 
progressed following prior EGFR-TKI therapy. OS data was immature 
across the trials. The PFS and ORR benefits of conferred by osimertinib 
were consistent across subgroups regardless of race, EGFR subtype, or the 
presence of CNS metastases across trials. In the AURA study, 60 patients re-
ceived osimertinib as first-line therapy; the PFS and ORR benefits afforded 
by osimertinib were the basis for conducting FLAURA. Common AEs re-
ported in patients taking osimertinib include diarrhoea, rash, dry skin, 
paronchia, ILD and prolonged QT interval [3, 6-8]. Of the 52 serious AEs 
and seven deaths reported in AURA2, 11  and one fatality due to ILD were 
investigator assessed as treatment-related, respectively. Osimertinib lead to 
fewer permanent discontinuations compared to SoC EGFR-TKI or chemo-
therapy [3, 8]. 
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Several studies are underway to investigate osimertinib as monotherapy or 
in combination with other targeted therapies or immunotherapies to treat 
various stages of EGFR-mutated NSCLC. Ongoing phase III studies are 
evaluating osimertinib in as third-line therapy, following tumour resection 
with or without adjuvant chemotherapy (ADAURA), for the treatment of 
brain metastases (APOLLO), and in a real world setting (ASTRIS). TAT-
TON will evaluate osimertinib in combination with durvalumab, MET in-
hibitor AZD6094, or selumetinib in patients with advanced EGFR-mutated 
NSCLC. However, CAURAL and phase I TATTON were suspended when 
patients taking combination osimertinib with durvalumab experienced an 
increase in ILD [38]. Other approaches involve combinations with antiangi-
ogentic agents or anti-EGFR monoclonal antibodies such as ramucirumab or 
necitumumab. A phase Ib trial is investigating osimertinib in combination 
with navitoclax following resistance to prior EGFR-TKI therapy. The 
BOOSTER trial is investigating combination osimertinib and bevacizumab 
for patients with acquired T790M mutation. Other third generation TKIs in 
clinical development for NSCLC include olmutinib, nazartinib, mavel-
ertinib, avitinib, and lazertinib [20]. Trials involving third-generation 
EGFR-TKIs rociletinib and naquotinib as treatment for EGFR-mutated ad-
vance NSCLC were discontinued due to lack of efficacy versus first-
generation TKIs [20]. Direct comparison trials would be needed to evaluate 
osimertinib versus second-generation afatinib and other third-generation 
EGFR-TKIs. The resistance mechanisms to osimertinib need to be fully 
characterized for targeting by fourth-generation inhibitors. A new class of 
inhibitors, designed to target triple mutations thought to confer resistance to 
fourth-generation EGFR-TKIs, is also under development [20]. 
The cost of osimertinib, at the recommended dose of 80 mg per day, is € 
6,132.50 per month [33]. A median duration of treatment exposure of 16 
months of osimertinib treatment would cost approximately € 98,120.00. 
Since osimertinib is indicated for EGFR-mutated NSCLC with an incidence 
of 10–15% in Europe, osimertinib would cost between € 35,764,740.00–
53,647,110.00 annually with an additional cost of approximately £ 189.05 (~ 
€ 165.00) per Cobas® EGFR Mutation Test v2 [32]. At the monthly average 
wholesale price of € 6,132.50 per 80 mg tablet, osimertinib is more costly 
than other FDA-approved EGFR-TKIs, including afatinib (40 mg) at € 
2,176.13, gefitinib (250 mg) at € 2,300.00, and erlotinib (150 mg) at € 1,809.77. 
While the National Institute for Health and Care Excellence (NICE) and the 
pan Canadian Oncology Drug Review Expert Review (pCODR) Committee 
recommended reimbursement for osimertinib for the treatment of EGFR-
mutated NSCLC following prior TKI therapy, cost-effectiveness analyses 
should be performed following maturation of the OS data [4]. 
Overall, FLAURA is the first phase III, randomized, double-blind, compara-
tive trial to demonstrate that osimertinib substantially increases PFS and 
lowers the risk of disease progression compared to first-generation EGFR-
TKI as initial therapy for EGFR-mutated advanced NSCLC. The PFS bene-
fit was consistent across subgroups regardless of race, EGFR subtype, and 
presence of CNS metastases. OS and QoL data are needed to confirm pa-
tients achieve a clinically relevant benefit over time despite favourable toler-
ability. Currently, the optimal therapeutic sequencing of different genera-
tions of EGFR-TKI remains unknown. However osimertinib holds efficacy 
for brain metastases that represent a significant clinical problem in patients 
treated with first and second generation EGFR-TKIs. Further analyses are 
necessary to fully characterize the resistance mechanisms to osimertinib for 
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than other FDA-
approved EGFR-TKIs  
FLAURA: phase III RCT 
demonstrates benefit in 
PFS, as initial therapy 
for EGFR-mutated 
NSCLC 
 
 
optimal therapeutic 
sequencing of different 
generations of EGFR-
TKI remains unknown 
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targeting by fourth-generation inhibitors. A new class of inhibitors, designed 
to target a triple mutation thought to confer resistance to fourth-generation 
EGFR-TKIs, is also under development. 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [36] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
osimertinib NSCLC NC PFS 2b >6 months +8.7 
0.46 
0.37–0.57 
HR ≤0.65 AND 
Gain ≥3 months 
3 
-9% grade 3–4 AEs,  
-5% discontinuation - - 3 
Original 
ESMO-
MCBS 
osimertinib NSCLC NC PFS 2b >6 months +8.7 0.46 
0.37–0.57 
HR ≤0.65 AND 
Gain ≥3 months 
3 - - - 3 
Abbreviations: AJ = Adjustments; CI = confidence interval; FM = final adjusted magnitude of clinical benefit grade; HR = hazard ratio, m = months; MG = median gain; NSCLC = non-small cell lung cancer; PE = primary 
endpoint; PFS = progression-free survival; PM = preliminary magnitude of clinical benefit grade; QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
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12 Appendix  
Table 4: Administration and dosing of osimertinib or standard of care TKI [2, 3, 28, 29] 
 Osimertinib 
SoC TKI 
(gefitinib or erlotinib) 
Administration 
mode 
Orally, once/day with or without food; pa-
tients with difficulty swallowing may dis-
perse tablet in 2 ounces of un-carbonated 
water [2] 
Gefitinib orally once/day with or without food; 
patients with difficulty swallowing may im-
merse tablet in 4–8 ounces of water [28]; erlo-
tinib orally on an empty stomach [29] 
Description of 
packaging 
80 mg beige, oval, tablets marked “AZ 80” 
on one side, supplied in bottles of 30 tablets; 
40 mg round tablets are also available in 
bottles of 30 [2] 
Gefitinib: 250 mg brown film-coated tablets, 
debossed “IRESSA 250,” supplied in bottles of 30 
tablets [28] 
Erlotinib: 150 mg white film-coated tablets, 
printed “T150,” supplied in bottles of 30 tablets 
[29] 
Total volume con-
tained in packag-
ing for sale 
30-tablet bottle of 80 mg dose contains 30 
tablets (80 mg/tablet, 80 mg/day); 30-tablet 
bottle of 40 mg dose pack contains 30 tab-
lets (40 mg/tablet, 40 mg/day) under specif-
ic circumstances [2, 3] 
30-tablet bottle of 250 mg gefitinib contains 30 
tablets (250 mg/tablet, 250 mg/day) [28] 
30-tablet bottle of erlotinib contains 30 tablets 
(150 mg/tablet, 150 mg/day) [29] 
Dosing 
80 mg/day; discontinue in patients with 
ILD/pneumonitis, prolonged QTc interval, 
symptomatic CHF or LVD ≥4 weeks; with-
hold if AEs of grade ≥3 or QTc interval ≥500 
msec on 2 separate ECGs; if baseline QTc is 
≥481 msec, resume at 40 mg. If AEs improve 
to grade 0-2 within 3 weeks, resume at 80 
mg or 40 mg daily [2]. 
250 mg/day of gefitinib or 150 mg/day of erlo-
tinib may be reduced to 10 mg/day. Discontinue 
gefitinib or erlotinib in patients with ILD, severe 
hepatic impairment, ulcerative keratitis, or GI 
perforation. Withhold gefitinib for grade ≥2 
ALT and/or AST elevations, ocular disorders, 
grade ≥3 diarrhoea, or skin disorders [28, 29]. 
Median treatment 
duration 
Until DP or unacceptable toxicity or as long 
as there is clinical benefit; median DTTE was 
16.2 months (range 0.1–27.4) [3] 
Until DP or unacceptable toxicity; median DTTE 
was 11.5 months (range 0-26.2) for SoC TKI [3] 
Contraindications None [2] None [28, 29] 
Drug interactions 
Increase to 160 mg/day in patients receiving 
strong CYP3A inducers or avoid them [2].  
Increase gefitinib to 500 mg/day with CYP3A4 
inducers, avoid PPIs, monitor INR with warfarin 
[28].  
Erlotinib concentrations increase with CYP3A4 
inhibitors, decrease with CYP3A4 or CYP1A2 in-
ducers; and drugs that alter pH alter absorption 
[29]. 
Abbreviations: AE = adverse events; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CHF = congestive heart 
failure; DDTE = duration of total treatment exposure; DP = disease progression; ECG = electrocardiogram; GI = gastrointestinal; 
ILD = interstitial lung disease; INR = international normalized ratio; LVD = left ventricular dysfunction; PPI = proton pump in-
hibitor; QTc = QT interval corrected for heart rate 
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Table 5: Characteristics of the FLAURA trial 
Title: Osimertinib in untreated EGFR-mutated advanced NSCLC (FLAURA) [3, 27] 
Study identifier NCT02296125, EudraCT2014-002694-11, D5160C00007, U1111-1160-2242, FLAURA 
Design International (29 countries), multicentre (132 sites), randomized, double-blind, comparative, phase III 
Duration of main phase: December 2014-March 2016 screened 994 patients; 556 pa-
tients randomized 1:1 to receive osimertinib (n=279) or SoC 
EGFR-TKI (n=277) 
Data cut-off: June 12, 2017; 136 (49%) osimertinib patients 
and 206 (74%) SoC EGFR-TKI patients experienced progres-
sion or death 
Median duration of follow-up for PFS: 15.0 months (range 0–
25.1) and 9.7 months (range 0–26.1) for osimertinib and SoC 
groups, respectively 
Duration of Run-in phase: Not applicable 
Duration of Extension phase: After data cut-off, 141 (56%) osimertinib and 64 (23%) SoC 
EGFR-TKI patients continued receiving trial treatment; 55 
(43%) of SoC EGFR-TKI patients received osimertinib (48 on 
crossover, 7 outside of the trial as second line treatment) 
Hypothesis 
Superiority 
The study was designed to assess the safety and efficacy of osimertinib in patients with previously 
untreated EGFRm-positive advanced NSCLC compared to SoC EGFR-TKIs, gefitinib or erlotinib.  
Funding AstraZeneca 
Treatments groups 
 
Osimertinib 
(n= 279 efficacy; n=279 safety; n=141 
ongoing at data cut-off; n=82 treat-
ment post-discontinuation of osimer-
tinib) 
80 mg orally once daily, with or without food + placebo 
SoC EGFR-TKI until disease progression or unacceptable 
toxicity 
SoC EGFR TKI 
(n= 279 efficacy; n=277 safety; n=64 
ongoing at data cut-off; n=99 treat-
ment post-discontinuation of SoC 
EGFR-TKI; n=48 cross-over to osimer-
tinib of which 30 were ongoing at data 
cut-off)   
  Gefitinib (n=183) 
  Erlotinib (n=94) 
 
SoC EGFR-TKI taken until disease progression or unac-
ceptable toxicity 
 
 
 
250 mg orally once daily + placebo osimertinib 
150 mg orally once daily + placebo osimertinib 
Notes 
Treated beyond disease progression if patients continued to derive inves-
tigator-assessed clinical benefit 
 
Protocol amendment allowed SoC EGFR-TKI patients to cross over to 
open-label osimertinib after BICR-assessed progression and local or cen-
trally confirmed T790M mutation.  
Endpoints and definitions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Progression-free survival  
Primary endpoint 
 
PFS Time from randomization until progression (RECIST v1.1) 
or all-cause death, regardless of withdrawal or therapy 
prior to progression (approximately 11.5 months) 
Objective response rate 
Secondary endpoint ORR 
The number (%) of patients with measurable disease with 
at least 1 visit response of CR or PR (approximately 11.5 
months) 
Progression-free survival 
in T790M-positive or 
T790M–negative patients 
Secondary endpoint 
PFS 
Time from randomization until progression (RECIST v1.1) 
or all-cause death, regardless of withdrawal or therapy 
prior to progression (approximately 11.5 months) 
Overall survival 
Secondary endpoint OS 
Time from randomization until all-cause death (approxi-
mately 29 months) 
PRO by therapy satisfac-
tion CTSQ-16 Question-
naire 
Secondary endpoint 
CTSQ-16  
Questionnaire assesses satisfaction with and preference 
for chemo, hormonal, and biological therapies in either 
oral and/or IV form (approximately 2 months) 
Pharmacokinetics 
Secondary endpoint PK 
Pharmacokinetics exposure parameters derived from 
plasma concentrations (approximately 9 months) 
PRO of disease-related 
symptoms and HRQoL 
Secondary endpoint 
EORTC 
QLQ-C30 
30-item questionnaire measuring general cancer symp-
toms and function (approximately 20 months) 
Duration of response 
Secondary endpoint DOR 
Time from first response until progression or death (ap-
proximately 11.5 months) 
Disease Control Rate  
Secondary endpoint 
DCR Percentage of patients with a best overall response of CR, 
PR, or SD (approximately 11.5 months) 
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Endpoints and definitions 
(continuation) 
Depth of response 
Secondary endpoint 
DTOR 
Relative change in the sum of the longest diameters of 
RECIST target lesions at the nadir in the absence of new 
lesions or progression of non-target lesions compared to 
baseline (approximately 11.5 months) 
HRQoL by EORTC QLQ-
LC13 
Secondary endpoint 
EORTC 
QLQ-LC13 
Questionnaire measuring lung cancer symptoms and side 
effects from conventional chemo-and radiotherapy (ap-
proximately 20 months) 
Adverse events 
Secondary endpoint AEs 
AEs graded by CTCAE version 4.0 (expected average 13 
months) 
Database lock Last update posted February 2018 
Results and Analysis  
Analysis description Primary Analysis 
ITT: Primary endpoint was investigator-assessed PFS (RECIST version 1.1). A sensitivity analysis of PFS 
was performed on the basis of data from BICR of RECIST assessments for all the patients.  
Efficacy analyses, based on the full analysis set, included all randomly assigned patients. Safety anal-
yses consisted of all patients who received at least one dose of study drug.  
A log-rank test, stratified by race (Asian versus non-Asian) and mutation type (Ex19 del versus 
L858R), was used to compare PFS between treatment groups, Breslow approach to handle tied events. 
Data for patients without progression or death at the time of analysis were censored at the time of 
the last RECIST assessment.  
Approximately 359 events of progression or death in a total of 530 randomly assigned patients would 
provide 90% power to detect a hazard ratio of 0.71 at a two-sided alpha level of 5%.  
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion 
 Adults (aged ≥18 years) with pathologically confirmed LA or 
metastatic NSCLC not amenable to curative surgery or radi-
otherapy 
 Local or central confirmation of the EGFR exon 19 deletion 
(EX19 del) or p.Leu858Arg (L858R) EGFR mutation, alone or 
co-occurring with other EGFR mutations 
 Patients with CNS metastases whose condition was neuro-
logically stable were eligible 
 Any previous definitive treatment or glucocorticoid therapy 
had to be completed at least 2 weeks before initiation of the 
trial treatment 
 
Exclusion 
 Prior treatment with EGFR-TKIs or any systemic anti-cancer 
therapy for LA or metastatic NSCLC 
 Radiotherapy to ≥30% of bone marrow or with a wide field 
of radiation, or major surgery within 4 weeks of the first 
dose of study drug 
 Medications or supplements that induce cytochrome P450 
(CYP) 3A4, an alternative anti-cancer treatment, or an inves-
tigational drug within 5 half-lives of the compound or any of 
its related material 
 Concurrent and/or other active malignancy that requires 
treatment within 2 years of first dose of study drug 
 Spinal cord compression symptomatic and unstable brain 
metastases, except those who have completed definitive 
therapy, are not on steroids, have stable neurologic status 
for at least 2 weeks after completing definitive therapy and 
steroids 
 Severe or uncontrolled systemic diseases, including uncon-
trolled hypertension and active bleeding diatheses; or active 
infection including hepatitis B, hepatitis C and HIV 
 Refractory nausea and vomiting, chronic gastrointestinal 
disease, inability to swallow the formulated product, or pre-
vious significant bowel resection that precludes adequate 
absorption of osimertinib 
 Cardiac criteria involving: mean resting corrected QTc >470 
msec; abnormalities in rhythm, conduction or morphology 
of resting ECG; or factors that increase QTc prolongation or 
risk of arrhythmic events or unexplained sudden death <40 
years of age in first-degree relatives or concomitant medica-
tion that prolongs the QT interval 
 History of ILD, drug-induced ILD, radiation pneumonitis 
which required steroid treatment or clinically active ILD 
Characteristics Osimertinib 
(n = 279) 
Standard EGFR-TKI 
(n = 277) 
Total 
(n =5 56) 
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Abbreviations: AEs = adverse events; BICR = blinded independent central review; CR = complete response; CTCA = Common Terminology 
Criteria for Adverse Events; CTSQ = Cancer Therapy Satisfaction Questionnaire; DCR = disease control rate; DOR = duration of response; 
DTOR = depth of response; ECG = electrocardiogram; EGFR = Epidermal Growth Factor Receptor; EGFRm = EGFR sensitising mutation; 
HRQoL = health-related quality of life; HIV = human immunodeficiency virus; ILD = interstitial lung disease; IV = intravenous; LA = locally 
advanced; NSCLC = non-small cell lung cancer; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PR = 
partial response; PRO = patient reported outcomes; QTc = corrected QT interval; RECIST = Response Evaluation Criteria in Solid Tumours; SD 
= stable disease; SoC = standard of care; TKI = tyrosine kinase inhibitor; WHO = World Health Organization 
  
Analysis population 
(continuation) 
Median age (range), years 64 (26–85) 64 (35–93) 64 (26–93) 
Male, n (%) 101 (36) 105 (38) 206 (37) 
Race, n (%) 
  Caucasian 
  Asian 
  Other 
 
101 (36) 
174 (62) 
4 (1) 
 
100 (36) 
173 (62) 
4 (1) 
 
201 (36) 
347 (62) 
8 (1) 
Smoking status, n (%) 
  Never 
  Current 
  Former 
 
182 (65) 
8 (3) 
89 (32) 
 
175 (63) 
9 (3) 
93 (34) 
 
357 (64) 
17 (3) 
182 (33) 
WHO Performance Status, n (%) 
  O 
  1 
  Missing data 
 
112 (40) 
167 (60) 
0 
 
116 (42) 
160 (58) 
1 (<1) 
 
228 (41) 
327 (59) 
1 (<1) 
Histologic type, n (%) 
  Adenocarcinoma 
  Other 
 
275 (99) 
4 (1) 
 
272 (98) 
5 (2) 
 
547 (98) 
9 (2) 
Overall disease classification, n 
(%) 
  Metastatic 
  Locally advanced 
  Missing data 
 
 
264 (95) 
14 (5) 
1 (<1) 
 
 
262 (95) 
15 (5) 
0 
 
 
526 (95) 
29 (5) 
1 (<1) 
Metastases, n (%) 
  Visceral metastases 
  CNS metastases 
 
94 (34) 
53 (19) 
 
103 (37) 
63 (23) 
 
197 (35) 
116 (21) 
EGFR mutation type at  
randomization, n (%) 
  Exon 19 deletion 
  L858R 
 
 
175 (63) 
104 (37) 
 
 
174 (63) 
103 (37) 
 
 
349 (63) 
207 (37) 
EGFR mutation type by  
central test, n (%) 
  Exon 19 deletion 
  L858R 
  No mutation detected, invalid 
test, or no or inadequate sample 
 
 
158 (57) 
97 (35) 
 
24 (9) 
 
 
155 (56) 
90 (32) 
 
32 (12) 
 
 
313 (56) 
187 (34) 
 
56 (10) 
EGFR-TKI comparator, n (%) 
  Gefitinib 
  Erlotinib 
 
NA 
NA 
 
183 (66) 
94 (34) 
 
183 (66) 
94 (34) 
Applicability of evidence 
Population 
FLAURA was conducted in untreated patients with advanced NSCLC whose tumours harbour a local or 
centrally confirmed EGFR EX19del or L858R mutation. Alone or co-occurring with other EGFR muta-
tions. Patients with stable CNS metastases were also eligible. The study population had a median age 
of 64 years, 63% were female, 62% were Asian, 64% were never smokers, 21% had CNS metastases, 
63% and 37% harboured EX19del and L858R mutations, respectively. Study demographics and clinical 
characteristics are representative of the global population with EGFR-mutated advanced NSCLC. 
Intervention 
The dosage and administration of osimertinib used in FLAURA is consistent with the recommended 
dosage and administration and that determined in the dose-defining AURA study [6, 9]. Dose inter-
ruptions, reductions, and treatment beyond progression were allowed based on investigator-assessed 
continued clinical benefit. SoC patients were allowed to cross over to osimertinib following confirma-
tion of BICR-assessed progression and post-progression documented T790M-positive status.  
Comparators 
While first-generation reversible gefitinib and erlotinib were used as comparators, second-generation 
irreversible afatinib is currently available and may have formed a suitable comparison. However, afat-
inib irreversibly binds wild-type EGFR also, causing dose-limiting rash and diarrhoea.  
Outcomes 
While osimertinib improves PFS, ORR, DOR compared to SoC EGFR-TKI in FLAURA, OS data were not 
mature and QoL was not reported in this analysis. Some cases of CNS progression may have gone un-
detected as only patients with brain metastases were routinely scanned.  
Setting 
FLAURA was a multinational study conducted in 29 countries, approximately 62% of patients were 
Asian, 36% were Caucasian, and 1% were of other race.  
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [34, 40] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomised 1:1 to osimertinib SoC gefitinib or 
erlotinib using the IVRS/IWRS system. The actual EGFR-TKI was selected at a site/country level 
according to the country’s marketing authorisation prior to the site initiation. Patients stratified 
at randomisation based on EGFR mutation (Ex19del or L858R) and race (Asian or non-Asian).  
yes 
Adequate allocation concealment: The IVRS/IWRS assigns the bottles of study material to be 
dispensed to each patient. yes 
Blinding: 
Patient: patients received active osimertinib plus comparator-matching pla-
cebo or active comparator plus osimertinib-matching placebo. Active and 
placebo tablets are identical and presented in the same packaging to ensure 
blinding.  
yes 
Treating physician: The IVRS/IWRS assigns the bottles of study material to 
be dispensed to each patient. Patients received active osimertinib plus com-
parator-matching placebo or active comparator plus osimertinib-matching 
placebo. Active and placebo tablets are identical and present in the same 
packaging to ensure blinding. 
yes 
Outcome assessor: centralised randomisation and allocation; sensitivity 
analysis was planned to assess PFS by pre-defined subgroups yes 
Selective outcome reporting unlikely: primary endpoints include investigator-assessed PFS, OS, 
ORR, DOR, DCR, DTOR and safety. Other endpoints not included in this analysis include mature 
OS, QoL, pharmacokinetics as per protocol.  
yes 
No other aspects which increase the risk of bias: industry funded the study, assisted with study 
design, collected, analysed and interpreted the data; all authors reviewed the manuscript and 
had full access to study data, cross-over 
no 
Risk of bias – study level low-risk 
Abbreviations: DCR = disease control rate; DOR = duration of response; DTOR = depth of treatment response; EGFR-TKI = epidermal 
growth factor receptor tyrosine kinase inhibitor; IVRS/IWRS = interactive web response system; interactive web response system; OS = overall 
survival; PFS = progression-free survival; QoL = quality of life; SoC = standard of care 
 
 
